Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Wesley H. Kaupinen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 29
- Beta
- -0.17
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 30.56
Financials
Revenue
$0.00-100.0%Net Income
$-21.87MEBITDA
$-21.56MFree Cash Flow
$-12.85MEPS (diluted)
$-1.52Shares Outstanding (diluted)
14.36M+1315.6%Operating Expenses
$21.41MCash & Debt
$250.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-41.72M | $-3.71 |
| 2024 | $0.00 | $-17.43M | $-7.83 |
| 2023 | $0.00 | $18.69M | $14.74 |
| 2022 | $25.90M | $-33.28M | $-29.61 |
| 2021 | $31.42M | $-45.74M | $-56.69 |
Valuation
PVLAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
93+33.33%Social Signal Score
Mentions (7)
- Newsseekingalpha.com·6d ago·Neutral
…ulatory risk is now significantly reduced, with the FDA awarding a third year of OOPD funding post-positive Phase 3 results and no further efficacy studies required. PVLA's robust $250.6 million cash position supports manufacturing, regulatory, and launch efforts ahead of a targeted US commercial launch in H1 2027.
View source ↗ - Newsglobenewswire.com·8d ago·Negative
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Palvella Therapeutics Appoints James R. Treat, M.D. Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas
View source ↗ - Newsglobenewswire.com·34d ago·Positive
…rticipate in Upcoming Healthcare Investor Conferences WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, …
View source ↗ - Newsglobenewswire.com·36d ago·Negative
Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and establish a new standard of care for an estimated more than 30,000 pediatric and adult patients living with microcystic lymphatic malformations in the U.S.
View source ↗ - Newsseekingalpha.com·48d ago·Neutral
…l Flywheel Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and commercial platform, aiming to expand QTORIN across multiple mTOR-driven dermatological indications, supporting a multi-indication commercial flywheel. Strong liquidity from a recent $230M equity raise enables PVLA to invest in commercialization and pipeline expansion, mitigating typical sm…
View source ↗ - Newsmarketbeat.com·50d ago·Negative
Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin, moving toward a planned New Drug Application submission for microcystic lymphatic malformations.
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-1.80 per share
Typical surprise -18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$-1.52 vs $-1.17miss
- Thu, May 7$-1.20 vs $-0.90miss
- Tue, Mar 31$-1.08 vs $-0.91miss
- Tue, Nov 11$-1.03 vs $-0.85miss
- Thu, Aug 14$-0.86 vs $-0.78miss
- Thu, May 15$-0.74 vs $-3.40beat
Estimates and results for PVLA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PVLA officers and directors.
- Bought
- $850k
- Sold
- $8.9m
3 trades
40 trades
- Goin Kathleensold
- Goin Kathleensold
- Goin Kathleensold
- Jenkins George Msold
- Jenkins George Msold
- Jenkins George Msold
- Jenkins George Msold
- Jenkins George Msold
57 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PVLA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.